SCHEMBL2791364

SCHEMBL2791364

Cc1c(C(=O)O)c(O)c2ccccc2c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ DPP4 P27487 1/20 0.46
▸ PDE10A Q9Y233 4/20 0.45
▸ LDHA P00338 3/20 0.42
▸ LDHB P07195 3/20 0.42
▸ TSHR P16473 2/20 0.41
▸ DHODH Q02127 6/20 0.41
▸ THRB P10828 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ ALOX12 P18054 1/20 0.41
▸ ATIC P31939 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5162563 0.85 PDE10A (0.50) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL19203141 0.79 LDHA (0.49) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL6171244 0.79 PDE10A (0.49) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL30706629 0.79 LDHA (0.49) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL2790721 0.79 PDE10A (0.45) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL4415520 0.78 HSD17B10 (0.54) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL31414101 0.78 HSD17B10 (0.54) KMT2AHPGDHSD17B10ALDH1A1KDM4E
SCHEMBL28184860 0.77 PDE10A (0.47) KMT2AHPGDALDH1A1KDM4EMEN1
SCHEMBL10905133 0.76 LDHA (0.43) HPGDHSD17B10ALDH1A1KDM4EPDE10A
SCHEMBL2790306 0.76 CYP2C19 (0.47) KMT2AHPGDHSD17B10ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US claimed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 — — CN claimed
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 — — US disclosed
CN-101175720-A Novel haloalkyl sulfone substituted compounds useful for the treatment of obesity and diabetes NOVO NORDISK AS (DK) 2008-05-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A KMT2A 3302/4885HPGD 2252/4885HSD17B10 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback